Intravitreal bevacizumab for idiopathic choroidal neovascularization.
An otherwise healthy 8-year-old girl with active juxtapapillary choroidal neovascularization was successfully treated with two intravitreal injections of bevacizumab. Intravitreal bevacizumab was well tolerated, choroidal neovascularization involuted, and subretinal and intraretinal serous fluid resorbed, with improvement in visual acuity from 20/400 to 20/50. The girl has remained stable for 6 months after the injections.
Cakir
Mehmet
M
Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey. drmcakir@hotmail.com
Cekiç
Osman
O
Yilmaz
O Faruk
OF
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007267:Injections; D014792:Visual Acuity / Q000187:drug effects*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab